Health Care & Life Sciences » Pharmaceuticals | GreenPeptide Co. Ltd.

GreenPeptide Co. Ltd. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
90
824
2,555
4,951
6,529
4,901
Total Accounts Receivable
141
102
118
55
77
1
Inventories
135
149
36
42
28
-
Other Current Assets
21
81
82
192
267
260
Total Current Assets
387
1,156
2,791
5,239
6,900
5,162
Net Property, Plant & Equipment
7
45
49
116
266
91
Total Investments and Advances
3
24
24
-
-
-
Long-Term Note Receivable
-
-
2
-
-
-
Intangible Assets
-
2
11
14
14
-
Other Assets
-
-
-
39
56
52
Total Assets
397
1,227
2,877
5,408
7,236
5,304
Accounts Payable
100
58
66
23
9
Income Tax Payable
2
5
10
25
35
Other Current Liabilities
90
116
52
114
185
Total Current Liabilities
192
179
129
161
229
Provision for Risks & Charges
15
22
26
42
52
Deferred Taxes
-
2
2
4
5
Total Liabilities
207
203
157
207
285
Common Equity (Total)
59
778
2,721
5,200
6,951
Total Shareholders' Equity
189
1,024
2,721
5,200
6,951
Total Equity
189
1,024
2,721
5,201
6,951
Liabilities & Shareholders' Equity
397
1,227
2,877
5,408
7,236
Accumulated Minority Interest
-
-
-
1
-
Preferred Stock (Carrying Value)
130
246
-
-
-

About GreenPeptide Co.

View Profile
Address
Fukuoka Bio Incubation Center 402
Kurume Fukuoka 839
Japan
Employees -
Website http://www.brightpathbio.com
Updated 07/08/2019
BrightPath Biotherapeutics Co., Ltd. engages in the drug development business. It focuses on the development of cancer immunotherapies. Its product candidates are based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.